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Many strategies may guide improved pain treatment. Among these are: 1) translational research 
(e.g. clinical trials of novel therapies emerging from basic science); 2) population research (e.g. 
identify pain burden-pain care health service gaps and describe treatment harms); and, 3) primary 
care research (e.g. describe patient presentation/referral patterns, treatment preferences/goals, 
develop patient care models/pathways). As in Figure 1, convergence of these strategies can help 
determine who needs treatment, whether treatments are effective, and how to administer 
treatments. 
 
Evidence from randomized controlled trials (RCTs) guides early implementation of new treatments 
and represents the translational link between preclinical research and patient care 
[25,30,55,65,99]. Controlled phase 1, 2 and 3 RCTs demonstrate safety and efficacy to justify 
marketing approval of new treatments [23,34,36,98,100]. Knowledge synthesis of multiple RCTs of 
a treatment, e.g. systematic reviews and meta-analyses, facilitates evidence-based clinical 
decisions [1,59,64]. “Evidence-based medicine” facilitates treatment selection based on 
consideration of all available safety and efficacy evidence, sometimes including non-controlled 
studies and expert opinion [29,40,43,80]. 
 
The narrow focus of phase 1-3 RCTs necessitates additional, larger, phase 4 post-marketing studies 
for safety and efficacy evidence in broader populations [11,75]. However, even phase 4 studies 
have limitations in generalizing to widespread use, and post-marketing recognition of problems 
with anti-inflammatory drugs [47,63] and opioids [21,56] has emphasized important gaps between 
RCTs and real-world practice [62]. Furthermore, statistically significant efficacy (e.g. treatment-
placebo difference) in RCTs sometimes translates to a questionably meaningful effect [24,40,73]. 
Such gaps are related to differences in RCT, versus real-world, conditions and emphasize the need 
for pharmacoepidemiologic, database-driven and other large cohort population research 
[38,39,82]. 
 
Most patient encounters involve primary care providers [20,86,87,94] and challenges in this 



































































[66,94]. Further challenges include identifying safe, cost-effective and evidence-based multimodal 
interventions [17,31,66] and revising practices in response to emerging evidence [41]. As in Figure 
2, evaluating a new treatment evolves through stages of translational, population-based and 
primary care research. This article reviews challenges to implementation of pain treatments that 
may be overcome with closer integration of 1) population-based, 2) translational, and 3) real-
world, primary care research. 
 
2. Population-based research on chronic pain burden and impact of pain treatment 
 
Chronic pain is a major contributor to the global health burden of non-fatal disease [9,95]. Pain 
treatment trials should therefore be implemented as part of a complex set of strategies to prevent 
and control the population impact of pain. Thus, RCTs can inform both chronic pain prevention but 
also chronic pain burden reduction. Complementary to RCTs, pharmacoepidemiology – the study 
of the use and effects of drugs in large numbers of people [90] – is characterized by various 
epidemiological methods, study designs, and data sources to examine patterns of medication use 
and associated population impact. This impact is broadly defined to include benefits and the 
harms of medicine use across different population levels (individuals, communities, and 
population as a whole). 
 
Also, a population perspective may identify evidence-burden gaps in existing trials, and future 
questions where evidence is most needed. For example, chronic pain prevalence is associated with 
ageing and analgesic use is common in older (e.g. >65 years old) patients [49], yet this population 
is commonly excluded from RCTs [6]. Another critical gap in the generalizability of pain RCTs is the 
recognition that a substantial number of people with chronic pain have multiple pain etiologies 
and anatomical pain sites, as well as other coexisting multimorbidities [74] that often exclude 
them from classical RCTs with tight exclusion criteria. These well-recognized problems for RCTs – 
in many areas – reveal a limited understanding of drug-drug, and drug-disease interactions 




































































As evidence of an important evidence-burden gap, a recent analysis compared registered RCTs 
within 27 disease groupings against burden of disease data across seven global regions [3]. This 
study found a widespread mismatch between trials and disease burden for musculoskeletal 
conditions in all income level strata. Furthermore, other differences – with respect to pain 
prevalence and treatment – in sex/gender [51], race/ethnicity [14;33] and comorbidities [74] 
suggest other important evidence-burden gaps in real-world pain treatment and research. 
 
Thus, evidence suggests a mismatch between trials and population pain burden, and that closer 
alignment between RCTs and population-focused studies would better contribute to chronic pain 
prevention and control at a population level. 
 
3. Methodology of translational RCTs and barriers to their implementation into clinical practice 
A prototypical design for a phase 3 trial involves parallel randomization of participants to two or 
more treatment arms including: 1) the study treatment, 2) a placebo control, and 3) a different 
dose of the study treatment, or a different treatment comparator [25,96]. A major trial design 
focus is internal validity (e.g. precision and accuracy), and minimization of bias, requiring random 
allocation of participants to treatment group, blinding of participants and researchers to 
treatment allocation, and other important factors including sample size, treatment duration, and, 
duration/completeness of outcome follow-up [1,48].  
 
Broadly, RCTs, which are diverse in design and purpose, collectively strive for internal validity (e.g. 
assay sensitivity), external validity (e.g. generalizability), risk-benefit evaluation and cost-benefit 
evaluation (Figure 3). However, RCTs vary depending on the purpose and research question. An 
important dichotomy articulated by Schwartz and Lellouch, was between an ‘explanatory’ trial – 
aiming to demonstrate a biological principle – versus a ‘pragmatic’ trial – aiming to guide 
treatment choices [83]. This dichotomy remains relevant with divergent purposes such as: 1) 
industry-sponsored RCTs to demonstrate safety and efficacy to support marketing a new 
treatment; and 2) ‘academic’ RCTs of available treatments to inform best practices. Explanatory 
trials – commonly product development trials scrutinized by regulatory agencies – focus on 



































































a less effective or ineffective treatment) [26]. Pragmatically oriented trials emphasize clinical 
importance of outcomes and treatment differences as well as generalizability (external validity) 
[24,76,77,97]. In new treatment development, ‘phase 3’, confirmatory trials inform the decision to 
market the product [23,34,36,98]. Fairly recently, the PRECIS-2 tool was validated for the purpose 
of guiding the design of clinical trials along a continuum from “very explanatory” to “very 
pragmatic” [61]. In this paper we mostly focus on RCTs of pharmacological pain therapies, as this is 
where most of the evidence currently exists. However, the principles and challenges discussed 
generally also apply to trials of nonpharmacological approaches, including multimodal, 
interdisciplinary management [52;53], which generally require more complex study designs [8;57]. 
 
RCTs need a study population sufficiently homogeneous to facilitate recruitment efficiency and 
maximize assay sensitivity; yet sufficiently broad and generalizable. Barriers to RCT generalizability 
[76,77] include trials conducted in populations with different socio-demographic characteristics 
different from the target healthcare setting, , or in healthcare systems with different access or 
health insurance criteria. Further, the use of participant selection criteria that exclude important 
patient subgroups or comorbidities limits applicability of findings. Major psychiatric disease [93], 
cognitive dysfunction [81], and substance use disorder [70] are some examples of patients that 
might be problematic in a trial (e.g. risk of unreliable/incomplete data), but who would benefit 
from relevant evidence in clinical practice. Thus, consideration is needed on how to conduct trials 
in complex and high pain burden patient populations [28]. Here, there may be a role for pragmatic 
trials, conducted in real-world practice, with populations that represent those at whom the 
intervention is targeted (e.g. co-existing conditions, primary care setting). Some of these issues of 
external validity and applicability to real-world practice may be addressed with relatively novel 
pragmatic trial designs [32,78] such as: 1) a cluster randomised trial design whereby study 
interventions are randomized at the level of the practitioner, or healthcare institution – instead of 
at the level of the patient [20]; 2) an enriched enrolment randomised withdrawal design, which 
include only those who tolerate and respond to the treatment [37; 68]; and, 3) a stepped wedge 




































































Selection of trial outcome measures is also critical [22,35,50,91,92]. In 2003, the “IMMPACT” 
group of authors (immpact.org) with expertise in pain research, drug regulation and the pain 
therapeutics industry recommended the following core outcome domains for pain trials: pain, 
physical and emotional function, treatment satisfaction, participant disposition through the trial 
(e.g. early withdrawal due to adverse effects) and treatment-emergent adverse events [22,91]. 
Since most novel pain therapies have demonstrated efficacy in preclinical models of nociception 
and pain [34], it is logical that pain intensity be used as a primary outcome measure. However, in 
practice, pain management does not always result in substantial reductions in pain intensity. This 
may be due to limited treatment efficacy, dose-limiting treatment side effects, or, analgesia-
related increases in physical activity that subsequently increase pain. Despite this, pain 
management may result in other benefits including improved coping, physical function, mood and 
sleep even if pain intensity reduction is not always apparent. In this regard, it is interesting to note 
recent evidence suggesting that the use of a composite outcome measure of both pain intensity 
and physical function may facilitate improved assay sensitivity of chronic pain RCTs [52] and so, 
perhaps trials need not rely exclusively on pain intensity as a primary outcome measure. Thus, 
evidence from trials, reportedly ‘positive’ for the primary outcome of pain intensity, should be 
carefully evaluated with respect to other secondary outcomes (e.g. function, mood, sleep) [71] 
and important adverse effects to put the treatment in appropriate clinical context for real-world 
practice [73]. In terms of treatment safety, evidence emphasizes the need to improve assessment 
and reporting of treatment-emergent adverse effects in pain trials [88,89], and further, to consider 
emerging population-based evidence of potential treatment-related harms of currently used pain 
treatments [21,47,56,63]. 
 
Rigorous systematic review and meta-analysis is necessary to synthesize evidence from multiple 
RCTs [64]. A commonly used metric in pain trial meta-analyses is the “number-needed-to-treat” 
(NNT). NNT is the inverse of the absolute risk reduction in a group of trials, and represents the 
average number of individuals who need to be treated in order for one to obtain pain relief (e.g. 
30% pain reduction). However, this hides a wide range of individual variation in responses: a high 
NNT could represent an intervention with which every recipient obtains just a little relief, or one 



































































an NNT of 7.2 for neuropathic pain in a recent systematic review [31], but Moore et al [67] 
demonstrated its use in a trial involving 200 people with fibromyalgia in which the range of relief 
obtained was 0 to almost 100%. Their message was, “Expect analgesic failure; pursue analgesic 
success” – in other words, even when a drug’s NNT, based on high quality trials, is high, there is 
still a chance of success with its use in individuals, so long as careful follow-up and early review 
empowers its cessation in the event of insufficient pain relief [67]. 
 
Further translation of trial-based evidence into real-world practice requires input from multiple 
disciplines as proposed by the GRADE (Grading of Recommendations Assessment, Development, 
and Evaluation) process. GRADE integrates quality of evidence, balance between beneficial and 
adverse effects, consideration of patient/public values and preferences and related use of 
resources [4,5,42]. For example, the IASP Neuropathic Pain Special Interest Group conducted a 
review of neuropathic pain pharmacotherapy involving systematic review and meta-analysis of 
treatment-specific trials, GRADE assessment and, ultimately, treatment recommendations [31]. 
 
4. Implementation of research evidence into real-world, primary care, chronic pain management 
and research strategies 
 
Due to the need for a comprehensive assessment and differential diagnosis of a presenting pain 
complaint, primary care physicians are commonly one of the first healthcare providers to evaluate 
an emerging chronic pain condition and to initiate early treatment approaches. Primary care has 
been defined as ‘first-contact, accessible, continued, comprehensive and coordinated care’ [101]. 
It is characterized by numerous, brief appointments between patients and multi-disciplinary 
healthcare professionals led by general practitioners. A primary care consultation (typically 10 
minutes) is multi-factorial and restricted by the short time available [72]. Thus, ready access to 
evidence about treatment interventions is essential to effective primary care – particularly 
relevant to pain management, which accounts for 22% to 50% of primary care consultations (while 
only 0.3% to 2% with chronic pain are referred to specialist pain clinics) [86]. Recognition of time 
constraints and patient complexity has encouraged a medical model with prescribed medicines, 



































































patient and professional [15]. However, it has been recently noted that an emphasis on prescribed 
medicines may preclude alternative or complementary non-pharmaceutical approaches such as 
self-management, physical, and psychological therapies [85] that are more time intensive. This has 
led to the introduction and study of alternative care models [60] including: 1) ‘stepped care’ – 
provision of condition-specific, guideline-based treatments with a progression to more complex or 
invasive intervention as required [27]; 2) ‘stratified care’ – provision of treatment intensiveness 
and comprehensiveness according to patient factors (e.g. low, medium and high risk) [7]; and 3) 
‘matched’ care – individualizing specific treatments to patient factors that predict need or 
favourable response [2]. Furthermore, the optimal implementation of such novel health care 
models require adoption, scalability and sustainability at a health system level [10]. 
 
Although efforts to improve implementation of, and access to, nonpharmacological pain 
treatments are expanding, the current reality is that analgesic drug prescribing remains one of the 
most common examples of pain management in primary care settings. Safe and effective analgesic 
prescribing requires careful discussion and frequent review, often with slow titration to 
appropriate effective and tolerated doses. This is difficult to achieve with traditional physician-led 
primary care. Alternative models of care are therefore required, including non-medical 
prescribing, nurse- or pharmacist-led pain clinics, and shared decision support systems. 
“Independent Prescribing” is available in the UK, with training and qualifications, to non-physician 
health professionals [19]. With required qualifications, they can prescribe medicines within their 
level of expertise. One study found that pain was the second most prevalent area for which nurses 
prescribed [18]. Studies of nurse-led, or pharmacist-led, pain clinics reported efficient and 
effective results and favourable treatment outcomes [12,44,45,58,79]. Building on this, Scotland 
has developed a national prescribing strategy that combines evidence with results of locally 
implemented prescribing approaches [69]. Decisions based on risk-benefit considerations can be 
facilitated by Clinical Decision Support Systems that follow algorithms integrated into healthcare 
computer systems and patient-facing apps. These under development for chronic pain [84]. 
As alluded to above, lessons learned from the opioid crisis have emphasized the potential value of 
expanding implementation and access to nondrug treatments for pain as well as pain 



































































interdisciplinary pain treatment teams led by psychologists and other, non-physician, health 
professionals have been successful for many years in some places, and emerging evidence 
suggests that chronic pain patients treated at facilities that provide nondrug pain treatments are 
less likely to initiate long term opioid therapy [13]. Thus, with a growing impetus to pursue 
nondrug pain treatments, such as various physical and psychological interventions, the synthesis 
and implementation of RCT evidence of these interventions is similarly needed [16; 54]. 
 
5. Conclusion 
This review highlights barriers to the implementation of RCT evidence into patient care. At a 
population level, continued efforts to identify various populations with high pain burden should be 
coupled with new RCTs involving comparable, high pain burden, populations. Given the short 
duration of RCTs, more pharmacoepidemiologic studies are needed to describe harms with long-
term, real-world, use of pain treatments, often used differently than they were in RCTs. 
 
Challenges of treating pain in patients with comorbid conditions (e.g. depression, substance 
abuse, dementia) – that are commonly excluded from traditional RCTs – suggest a need for trials 
that feasibly include such complex patients. Other future improvements require RCTs to focus on 
populations with greater pain burden through careful attention to patient factors such as 
sex/gender, age, race/ethnicity, socioeconomic status, geographical location and access to 
healthcare. 
 
Implementing trial evidence into primary care requires expansion of resources, including a 
broader range of health professionals, to effectively replicate treatment conditions followed in 
RCTs. Further implementation success requires synthesis and translation of evidence into 
treatment guidelines, patient care pathways and community-oriented treatment strategies in the 




































































Continued collaboration between population science, RCTs and primary care research will 
promote more effective implementation of emerging pain therapies to ultimately improve pain 
management patient outcomes. 
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Figure 1: Convergent input of translational, population-based, and primary care research into the 
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